 | |
| Founded | 1986 |
|---|---|
| Type | Self-funded organization |
| Location |
|
| Services | Bank and distribute hybridomas and cell products |
The Developmental Studies Hybridoma Bank (DSHB) is a National Resource established by the National Institutes of Health (NIH) in 1986 to bank and distribute at cost hybridomas and the monoclonal antibodies (mAbs) they produce to the basic science community worldwide. It is housed in the Department of Biology at the University of Iowa.
The mission of the DSHB is four-fold:
The DSHB is directed by David R. Soll at the University of Iowa. There are currently over 5000 hybridomas in the DSHB collection. [1] The DSHB has obtained hybridomas from a variety of individuals and institutions, the latter including the Muscular Dystrophy Association, the National Cancer Institute, the NIH Common Fund, and the European Molecular Biology Laboratory (EMBL). The DSHB eagerly awaits new contributions. First time customers must agree to the DSHB terms of usage that products will be used for research purposes only, and that they cannot be commercialized or distributed to a third party. Researchers also agree to acknowledge both the DSHB and the contributing investigator and institution in publications that benefit from the use of DSHB products and provide to the DSHB citations of all publications. Individuals or institutions can deposit hybridomas for distribution at no cost. Contributing to the DSHB does not preclude the depositor from licensing cell lines for commercial purposes. The DSHB does not own any contributed intellectual property. The intellectual property remains that of the scientist and/or institution that banks the hybridomas. The DSHB covers the operating costs of maintaining, improving, producing and distributing products in the collection.
The DSHB was created in 1986 by the NIH to bank and distribute hybridomas and the monoclonal antibodies (mAbs) they produce to the general scientific community in order to facilitate research. The DSHB was moved from Johns Hopkins University to the University of Iowa in 1996, and placed under the directorship of David R. Soll. The DSHB has been self-funded since 1997 and relies on no outside funding.
Nobel Prize and Alfred P. Sloan, Jr. Prize winner J. Michael Bishop deposited the anti c-MYC hybridoma 9e 10
Nobel Prize winner Sir John Gurdon deposited MyoD clone D7F2
Nobel Prize winner Eric F. Wieschaus deposited 7 hybridomas
National Academy of Sciences Members who have deposited hybridomas
An antibody (Ab), also known as an immunoglobulin (Ig), is a large, Y-shaped protein used by the immune system to identify and neutralize foreign objects such as pathogenic bacteria and viruses. The antibody recognizes a unique molecule of the pathogen, called an antigen. Each tip of the "Y" of an antibody contains a paratope that is specific for one particular epitope on an antigen, allowing these two structures to bind together with precision. Using this binding mechanism, an antibody can tag a microbe or an infected cell for attack by other parts of the immune system, or can neutralize it directly.
Stanley Ben Prusiner is an American neurologist and biochemist. He is the director of the Institute for Neurodegenerative Diseases at University of California, San Francisco (UCSF). Prusiner discovered prions, a class of infectious self-reproducing pathogens primarily or solely composed of protein, considered by many as a heretical idea when first proposed. He received the Albert Lasker Award for Basic Medical Research in 1994 and the Nobel Prize in Physiology or Medicine in 1997 for prion research developed by him and his team of experts beginning in the early 1970s.
A monoclonal antibody is an antibody produced from a cell lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell.
In the field of bioinformatics, a sequence database is a type of biological database that is composed of a large collection of computerized ("digital") nucleic acid sequences, protein sequences, or other polymer sequences stored on a computer. The UniProt database is an example of a protein sequence database. As of 2013 it contained over 40 million sequences and is growing at an exponential rate. Historically, sequences were published in paper form, but as the number of sequences grew, this storage method became unsustainable.
An epitope, also known as antigenic determinant, is the part of an antigen that is recognized by the immune system, specifically by antibodies, B cells, or T cells. The part of an antibody that binds to the epitope is called a paratope. Although epitopes are usually non-self proteins, sequences derived from the host that can be recognized are also epitopes.
The European Molecular Biology Laboratory (EMBL) is an intergovernmental organization dedicated to molecular biology research and is supported by 28 member states, one prospect state, and one associate member state. EMBL was created in 1974 and is funded by public research money from its member states. Research at EMBL is conducted by approximately 110 independent research and service groups and teams covering the spectrum of molecular biology and bioinformatics. The list of Groups and Teams at EMBL can be found at www
Sir John Bertrand Gurdon is a British developmental biologist, best known for his pioneering research in nuclear transplantation and cloning.
Hybridoma technology is a method for producing large numbers of identical antibodies. This process starts by injecting a mouse with an antigen that provokes an immune response. A type of white blood cell, the B cell, produces antibodies that bind to the injected antigen. These antibody producing B-cells are then harvested from the mouse and, in turn, fused with immortal myeloma cancer cells, to produce a hybrid cell line called a hybridoma, which has both the antibody-producing ability of the B-cell and the longevity and reproductivity of the myeloma. The hybridomas can be grown in culture, each culture starting with one viable hybridoma cell, producing cultures each of which consists of genetically identical hybridomas which produce one antibody per culture (monoclonal) rather than mixtures of different antibodies (polyclonal). The myeloma cell line that is used in this process is selected for its ability to grow in tissue culture and for an absence of antibody synthesis. In contrast to polyclonal antibodies, which are mixtures of many different antibody molecules, the monoclonal antibodies produced by each hybridoma line are all chemically identical.
César Milstein, CH, FRS was an Argentine biochemist in the field of antibody research. Milstein shared the Nobel Prize in Physiology or Medicine in 1984 with Niels Kaj Jerne and Georges J. F. Köhler for developing the hybridoma technique for the production of monoclonal antibodies.
Eric Francis Wieschaus is an American evolutionary developmental biologist and 1995 Nobel Prize-winner.
Immunogenicity is the ability of a foreign substance, such as an antigen, to provoke an immune response in the body of a human or other animal. It may be wanted or unwanted:
A bispecific monoclonal antibody is an artificial protein that can simultaneously bind to two different types of antigen or two different epitopes on the same antigen. Naturally occurring antibodies typically only target one antigen. BsAbs can be manufactured in several structural formats. BsAbs can be designed to recruit and activate immune cells, to interfere with receptor signaling and inactivate signaling ligands, and to force association of protein complexes. BsAbs have been explored for cancer immunotherapy, drug delivery, and Alzeimer's disease.
A myc tag is a polypeptide protein tag derived from the c-myc gene product that can be added to a protein using recombinant DNA technology. It can be used for affinity chromatography, then used to separate recombinant, overexpressed protein from wild type protein expressed by the host organism. It can also be used in the isolation of protein complexes with multiple subunits.
Symphogen is a biotechnology company located in Copenhagen, Denmark that develops protein drugs based on recombinant monoclonal antibody mixtures. These drugs are different from the polyclonal antibodies, as each antibody in the mixture is produced from one carefully selected clone. Their three main areas of therapeutic research are immunoglobulin replacement, cancer, and infectious diseases. The company was founded in 2000 and has patents on a drug discovery platform called Symplex and a drug manufacturing platform called Sympress. By 2009, ten drugs were being developed with rozrolimupab (Sym001) being the lead product. Laboratoires Servier acquired Symphogen in 2020.
M30 Apoptosense® ELISA is an enzyme-linked immunosorbent assay developed for the detection of soluble caspase-cleaved keratin 18.
Gerd Jürgens is a plant developmental biologist and emeritus Director of the Cell Biology Department at the Max Planck Institute for Developmental Biology and Head of the Center for Plant Molecular Biology (ZMBP) at the Eberhard-Karls Universität Tübingen. He has published extensively in leading journals, including eight papers in the journal Nature as well as various articles in the journals Cell, Science, Journal of Cell Biology and The Plant Journal.
A rabbit hybridoma is a hybrid cell line formed by the fusion of an antibody producing rabbit B cell with a cancerous B-cell (myeloma).
David R. Soll is a professor of Biology at the University of Iowa. He is best known for the motion analysis of living cells, the discovery of Candida albicans phenotypic switching and monoclonal antibody technology.
Addgene is a non-profit plasmid repository. Addgene facilitates the exchange of genetic material between laboratories by offering plasmids and their associated cloning data to non-profit and academic laboratories around the world. Addgene provides a free online database of plasmid cloning information and references, including lists of commonly used vector backbones, popular lentiviral plasmids, and molecular cloning protocols.
Terry William Pearson is a Canadian biochemist, immunologist, educator and biotechnology entrepreneur.